► Customized research for SOLY vs. INO!
► All in one page research, scroll down. Compare two other stocks.
► Note: Don't forget to explore SpeculatingStocks further... from the SpeculatingStocks.com Homepage you can Discover Stocks, Post Anonymously, and React. No Login Required.
Done! Side by Side Research Below for SOLY vs. INO.
↗ Join Our Free Email Newsletter.
► Soliton Inc. vs. Inovio Pharmaceuticals, Inc.
Industry Match! Industry of Both SOLY and INO:
Health Care/Life Sciences
SOLY
Data Last Updated: 6 hours ago
↻ Update Column 1 to Most Recent
► Key Statistics
Cap: 175M
P/E: N/A
P/S: N/A
Q P/B: 24.37
Y Rev: -
Q Rev: -
Beta: N/A

SOLY Share Stats
► Outstanding Shares
15.69M
► Float Shares
6.35M
► Percent of Float Short
19.12%
SOLY Insider Stats
► Percent Outstanding Insider Ownership
4.89%
► Percent Outstanding Institution Ownership
12.48%
SOLY Social Stats
► Followers
0
► B/S Rating Today
0
► B/S Rating All-Time
N/A
Share SOLY Insights
SOLY Profile
► CEO
Mr. Christopher Capelli
► Exchange
Nasdaq
► Employees
8.00
► About
Soliton, Inc. is a medical development company. It develops healthcare technological devices for medical and cosmetic treatments. The firm's devices generate planar acoustic waves or shock waves in cosmetic surgical procedures, aesthetic surgical procedures, and dermatology...

SOLY Financials
Annual Financials
Income Statement
► Revenue
-
► Net Income
(9.31M)
Cash Flow Statement
► Change in Cash / Investments
115,023
Balance Sheet
► Cash / Investments
133,435
► Short Term Debt
10.57M
► Long Term Debt
None
► Total Current Assets
143,968
► Total Current Liabilities
21.08M
► Total Assets
1.6M
► Total Liabilities
21.16M
► Stockholder Equity
(19.56M)
Quarterly Financials
Income Statement
► Q Revenue
-
► Q Net Income
(4.29M)
Cash Flow Statement
► Q Change in Cash / Investments
(2.68M)
Balance Sheet
► Q Cash / Investments
8.71M
► Q Short Term Debt
None
► Q Long Term Debt
None
► Q Total Current Assets
8.91M
► Q Total Current Liabilities
2.73M
► Q Total Assets
9.93M
► Q Total Liabilities
2.74M
► Q Stockholder Equity
7.18M

SOLY Charts
► 10-Year Chart

► 5-Year Chart

► 1-Year Chart

► 6-Month Chart

► 3-Month Chart

► 1-Month Chart

► 1-Day Chart

INO
Data Last Updated: 6 hours ago
↻ Update Column 2 to Most Recent
► Key Statistics
Cap: 271M
P/E: N/A
P/S: 8.89
Q P/B: 8.04
Y Rev: 30.48M
Q Rev: 866,863
Beta: 2.14

INO Share Stats
► Outstanding Shares
98.03M
► Float Shares
96.19M
► Percent of Float Short
11.11%
INO Insider Stats
► Percent Outstanding Insider Ownership
4.99%
► Percent Outstanding Institution Ownership
64.73%
INO Social Stats
► Followers
1
► B/S Rating Today
0
► B/S Rating All-Time
+1
Share INO Insights
INO Profile
► CEO
Dr. J. Joseph Kim
► Exchange
Nasdaq
► Employees
281.00
► About
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's...

INO Financials
Annual Financials
Income Statement
► Revenue
30.48M
► Net Income
(96.97M)
Cash Flow Statement
► Change in Cash / Investments
(92,946)
Balance Sheet
► Cash / Investments
81.23M
► Short Term Debt
None
► Long Term Debt
None
► Total Current Assets
87.81M
► Total Current Liabilities
35.3M
► Total Assets
131.11M
► Total Liabilities
44.08M
► Stockholder Equity
86.94M
Quarterly Financials
Income Statement
► Q Revenue
866,863
► Q Net Income
(23.54M)
Cash Flow Statement
► Q Change in Cash / Investments
(3.88M)
Balance Sheet
► Q Cash / Investments
93.8M
► Q Short Term Debt
2.01M
► Q Long Term Debt
70.07M
► Q Total Current Assets
98.81M
► Q Total Current Liabilities
19.55M
► Q Total Assets
151.53M
► Q Total Liabilities
115.41M
► Q Stockholder Equity
33.69M

INO Charts
► 10-Year Chart

► 5-Year Chart

► 1-Year Chart

► 6-Month Chart

► 3-Month Chart

► 1-Month Chart

► 1-Day Chart

